CRISPR Therapeutics(US:CRSP) zacks.comยท2024-05-29 14:01Core Viewpoint - CRISPR Therapeutics AG has been a highly searched stock recently, indicating potential investor interest and market activity [1] Earnings Estimates - For the current quarter, CRISPR Therapeutics is expected to report a loss of $1.39 per share, reflecting a year-over-year change of -41.8% [5] - The Zacks Consensus Estimate for the current fiscal year is -$5.64, indicating a significant year-over-year change of -190.7% [5] - For the next fiscal year, the consensus estimate is -$4.50, showing a change of +20.1% from the previous year [6] - The consensus earnings estimate has changed +16.9% over the last 30 days for the current quarter and +9.6% for the current fiscal year [5][6] Revenue Growth Forecast - The consensus sales estimate for the current quarter is $8.21 million, indicating a year-over-year decline of -88.3% [10] - For the current fiscal year, the sales estimate is $89.12 million, reflecting a -76% change, while the next fiscal year estimate is $550.06 million, indicating a growth of +517.2% [10] Last Reported Results and Surprise History - In the last reported quarter, CRISPR Therapeutics generated revenues of $0.5 million, a year-over-year decline of -99.5% [11] - The EPS for the same period was -$1.43, compared to -$0.67 a year ago, with a revenue surprise of -93.94% against the Zacks Consensus Estimate [11] - The company has beaten consensus EPS estimates in the last four quarters and topped revenue estimates twice during this period [12] Valuation - CRISPR Therapeutics has a Zacks Value Style Score of F, indicating it is trading at a premium compared to its peers [16] - Valuation multiples such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF) are essential for assessing whether the stock is overvalued or undervalued [14][15] Overall Market Position - The Zacks Rank for CRISPR Therapeutics is 3 (Hold), suggesting it may perform in line with the broader market in the near term [7][17]